Tempest Therapeutics Inc.

AI Score

0

Unlock

0.92
-0.00 (-0.27%)
At close: Jan 14, 2025, 3:59 PM
0.92
0.16%
Pre-market Jan 15, 2025, 07:22 AM EST
undefined%
Bid 0.91
Market Cap 40.09M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.53
PE Ratio (ttm) -0.6
Forward PE n/a
Analyst Buy
Ask 0.92
Volume 809,940
Avg. Volume (20D) 3,136,634
Open 0.94
Previous Close 0.92
Day's Range 0.90 - 0.94
52-Week Range 0.70 - 6.00
Beta undefined

About TPST

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops T...

Industry Biotechnology
Sector Healthcare
IPO Date Nov 12, 2012
Employees 17
Stock Exchange NASDAQ
Ticker Symbol TPST

Analyst Forecast

According to 4 analyst ratings, the average rating for TPST stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 1315.35% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
2 months ago · Source
-10.5%
Tempest Therapeutics shares are trading lower afte... Unlock content with Pro Subscription
5 months ago · Source
+30.25%
Tempest Therapeutics shares are trading higher after the company announced feedback from its end-of-Phase 2 meeting with the FDA for amezalpat in combination with atezolizumab and bevacizumab to treat first-line unresectable or metastatic hepatocellular carcinoma.